Value of helical computed tomography and color doppler flowing imaging in assessing the resectability of pancreatic cancer
10.3760/cma.j.issn.1673-9752.2009.03.020
- VernacularTitle:螺旋CT和彩色多普勒血流显像检查对胰腺癌可切除性的评估价值
- Author:
Jingdong LI
;
Xiaoming ZHANG
;
Yi DAI
;
Yong PENG
;
Bo LI
;
Yong ZENG
;
Lünan YAN
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Helical computed tomography;
Color doppler flow imaging;
Resection
- From:
Chinese Journal of Digestive Surgery
2009;8(3):217-219
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the value of helical computed tomography (HCT) and color doppler flowing imaging (CDPI) in evaluating the resectability of pancreatic cancer. Methods The clinical data of 114 patients with pancreatic cancer who had been admitted to the Affiliated Hospital of North Sichuan Medical College from January 1995 to December 2002 were retrospectively analyzed. The values of HCT and CDPI in assessing the resectability of pancreatic cancer were determined according to the results of operation and pathological examina-tion. All the data were analyzed by chi-square test and Fisher exact probability. Results Of all patients, 109 were examined by HCT, 97 by CDPI and 96 by HCT+CDPI. For patients examined by HCT, the resection rates of pancreatic head cancer, pancreatic body and tail cancer and total pancreatic cancer were 45.3% (39/86), 26.3% (5/19) and 0 (0/9), respectively. The resection rate of pancreatic head cancer was higher than that of pancreatic body and tail cancer (χ2=8.965, P<0.05). With the increase of tumor size, the invasion rate and metastasis rate were increased and the resection rate was decreased (z=6.15, 5.35, 7.18, P<0.01). The sensitivity rate and specificity rate were 77.8% and 82.2% of HCT, 73.3% and 80.6% of CDPI, 90.6% and 92.4% of HCT+CDPI in assessing the resectability of pancreatic cancer. The values of Kappa identity test of HCT, CDPI and HCT+CDPI were 0.58, 0.52 and 0.82, respectively. Conclusions Combined application of HCT and CDPI can further improve the accuracy in assessing the resectability of pancreatic cancer.
